Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy

被引:76
作者
Guengoer, Deniz [1 ,2 ]
de Vries, Juna M. [1 ,3 ]
Hop, Wim C. J. [4 ]
Reuser, Arnold J. J. [1 ,5 ]
van Doorn, Pieter A. [1 ,3 ]
van der Ploeg, Ans T. [1 ,2 ]
Hagemans, Marloes L. C. [1 ,2 ]
机构
[1] Erasmus MC Univ Med Ctr, Ctr Lysosomal & Metab Dis, NL-3015 GJ Rotterdam, Netherlands
[2] Erasmus MC Univ Med Ctr, Dept Pediat, NL-3015 GJ Rotterdam, Netherlands
[3] Erasmus MC Univ Med Ctr, Dept Neurol, NL-3015 CE Rotterdam, Netherlands
[4] Erasmus MC Univ Med Ctr, Dept Biostat, NL-3015 GE Rotterdam, Netherlands
[5] Erasmus MC Univ Med Ctr, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands
来源
ORPHANET JOURNAL OF RARE DISEASES | 2011年 / 6卷
关键词
Pompe disease; survival; acid maltase deficiency; lysosomal storage disease; glycogen storage disease type II; prognostic factors; natural course; patient reported outcome measures; ACID ALPHA-GLUCOSIDASE; ALGLUCOSIDASE ALPHA; HANDICAP SCALE; FREQUENCY; CHILDREN;
D O I
10.1186/1750-1172-6-34
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Pompe disease is a rare lysosomal storage disorder characterized by muscle weakness and wasting. The majority of adult patients have slowly progressive disease, which gradually impairs mobility and respiratory function and may lead to wheelchair and ventilator dependency. It is as yet unknown to what extent the disease reduces the life span of these patients. Our objective was to determine the survival of adults with Pompe disease not receiving ERT and to identify prognostic factors associated with survival. Methods: Data of 268 patients were collected in a prospective international observational study conducted between 2002 and 2009. Survival analyses from time of diagnosis and from time of study entry were performed using Kaplan-Meier curves and Cox-proportional-hazards regression. Results: Median age at study entry was 48 years (range 19-79 years). Median survival after diagnosis was 27 years, while median age at diagnosis was 38 years. During follow-up, twenty-three patients died prior to ERT, with a median age at death of 55 (range 23-77 years). Use of wheelchair and/or respiratory support and patients' score on the Rotterdam Handicap Scale (RHS) were identified as prognostic factors for survival. Five-year survival for patients without a wheelchair or respiratory support was 95% compared to 74% in patients who were wheelchair-bound and used respiratory support. In a Dutch subgroup of 99 patients, we compared the observed number of deaths to the expected number of deaths in the age-and sex-matched general population. During a median follow-up of 2.3 years, the number of deaths among the Dutch Pompe patients was higher than the expected number of deaths in the general population. Conclusion: Our study shows for the first time that untreated adults with Pompe disease have a higher mortality than the general population and that their levels of disability and handicap/participation are the most important factors associated with mortality. These results may be of relevance when addressing the effect of ERT or other potential treatment options on survival.
引用
收藏
页数:8
相关论文
共 26 条
[1]  
[Anonymous], WHO INT CLASS FUNCT
[2]   Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling [J].
Ausems, MGEM ;
Verbiest, J ;
Hermans, MMP ;
Kroos, MA ;
Beemer, FA ;
Wokke, JHJ ;
Sandkuijl, LA ;
Reuser, AJJ ;
van der Ploeg, AT .
EUROPEAN JOURNAL OF HUMAN GENETICS, 1999, 7 (06) :713-716
[3]  
Engel A., 2004, Myology, V3
[4]   Impact of late-onset Pompe disease on participation in daily life activities: Evaluation of the Rotterdam Handicap Scale [J].
Hagemans, M. L. C. ;
Laforet, P. ;
Hop, W. J. C. ;
Merkies, I. S. J. ;
Van Doorn, P. A. ;
Reuser, A. J. J. ;
Van der Ploeg, A. T. .
NEUROMUSCULAR DISORDERS, 2007, 17 (07) :537-543
[5]   Disease severity in children and adults with Pompe disease related to age and disease duration [J].
Hagemans, MLC ;
Winkel, LPF ;
Hop, WCJ ;
Reuser, AJJ ;
Van Doorn, PA ;
Van der Ploeg, AT .
NEUROLOGY, 2005, 64 (12) :2139-2141
[6]   Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients [J].
Hagemans, MLC ;
Winkel, LPF ;
Van Doorn, PA ;
Hop, WJC ;
Loonen, MCB ;
Reuser, AJJ ;
Van der Ploeg, AT .
BRAIN, 2005, 128 :671-677
[7]  
Hirschhorn R., 2001, The Metabolic and Molecular Bases of Inherited Disease, P3389
[8]   RESPIRATORY-FAILURE AS INITIAL SYMPTOM OF ACID MALTASE DEFICIENCY [J].
KEUNEN, RWM ;
LAMBREGTS, PCLA ;
OPDECOUL, AAW ;
JOOSTEN, EMG .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1984, 47 (05) :549-552
[9]   Recombinant human acid α-glucosidase -: Major clinical benefits in infantile-onset Pompe disease [J].
Kishnani, P. S. ;
Corzo, D. ;
Nicolino, M. ;
Byrne, B. ;
Mandel, H. ;
Hwu, W. L. ;
Leslie, N. ;
Levine, J. ;
Spencer, C. ;
McDonald, M. ;
Li, J. ;
Dumontier, J. ;
Halberthal, M. ;
Chien, Y. H. ;
Hopkin, R. ;
Vijayaraghavan, S. ;
Gruskin, D. ;
Bartholomew, D. ;
van der Ploeg, A. ;
Clancy, J. P. ;
Parini, R. ;
Morin, G. ;
Beck, M. ;
De la Gastine, G. S. ;
Jokic, M. ;
Thurberg, B. ;
Richards, S. ;
Bali, D. ;
Davison, M. ;
Worden, M. A. ;
Chen, Y. T. ;
Wraith, J. E. .
NEUROLOGY, 2007, 68 (02) :99-109
[10]   Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease [J].
Kishnani, Priya S. ;
Corzo, Deya ;
Leslie, Nancy D. ;
Gruskin, Daniel ;
van der Ploeg, Ans ;
Clancy, John P. ;
Parini, Rosella ;
Morin, Gilles ;
Beck, Michael ;
Bauer, Mislen S. ;
Jokic, Mikael ;
Tsai, Chen-En ;
Tsa, Brian W. H. ;
Morgan, Claire ;
O'Meara, Tara ;
Richards, Susan ;
Tsao, Elisa C. ;
Mandel, Hanna .
PEDIATRIC RESEARCH, 2009, 66 (03) :329-335